Sirolimus-Induced Diffuse Alveolar Hemorrhage: A Case Report

BALCAN M. B., Simsek E., Ugurlu A. O., DEMİRALAY E., ŞAHİN S.

AMERICAN JOURNAL OF THERAPEUTICS, cilt.23, sa.6, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 6
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1097/mjt.0000000000000427
  • Dergi Adı: AMERICAN JOURNAL OF THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: sirolimus, lung, hemorrhage, steroid, PROLIFERATION SIGNAL INHIBITORS, RENAL-TRANSPLANT RECIPIENTS, OF-THE-LITERATURE, PULMONARY TOXICITY, RISK-FACTORS, PNEUMONITIS, EVEROLIMUS, ALLOGRAFT, THERAPY
  • Marmara Üniversitesi Adresli: Hayır

Özet

Sirolimus is a mammalian target of the rapamycin, a protein kinase, which is responsible for inhibition of T cell and B cell proliferation. Sirolimus has side effects on lugs, and may cause cryptogenic organizing pneumonia, diffuse alveolar hemorrhage, lymphocytic pneumonitis, hypersensitivity pneumonitis, desquamative interstitial pneumonia, and pulmonary alveolar proteinosis. Diagnosis is based on the combination of clinical, radiological, histological, and pathological investigation. We report a case of diffuse alveolar hemorrhage in a 33-year-old, female renal transplant recipient. After discontinuation of sirolimus, radiological images and clinical condition of the patient got better. We also planned steroid therapy for 6 months by tapering the dosage slowly. After steroid therapy, full recovery of pulmonary functions achieved, and the patient is observed in our outpatient clinic with lack of any pulmonary symptoms.